$163.73
1.25%
Nasdaq, Sep 02, 10:00 pm CET

Ligand Pharmaceuticals Incorporated Stock price

$163.73
+28.34 20.93% 1M
+51.55 45.95% 6M
+56.58 52.80% YTD
+57.93 54.75% 1Y
+106.47 185.95% 3Y
+100.78 160.10% 5Y
+107.37 190.49% 10Y
+156.14 2,057.18% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+2.02 1.25%

Key metrics

Basic
Market capitalization
$3.2b
Enterprise Value
$3.0b
Net debt
positive
Cash
$245.0m
Shares outstanding
19.4m
Valuation (TTM | estimate)
P/E
negative | 23.4
P/S
17.1 | 14.8
EV/Sales
15.8 | 13.7
EV/FCF
58.3
P/B
3.9
Financial Health
Equity Ratio
88.2%
Return on Equity
-0.5%
ROCE
-1.6%
ROIC
-2.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$187.6m | $216.2m
EBITDA
$18.7m | $81.9m
EBIT
$-14.3m | $29.7m
Net Income
$-75.9m | $135.9m
Free Cash Flow
$50.9m
Growth (TTM | estimate)
Revenue
40.5% | 29.4%
EBITDA
-53.9% | 46.4%
EBIT
-288.3% | 29.2%
Net Income
-281.0% | 3,471.2%
Free Cash Flow
450.9%
Margin (TTM | estimate)
Gross
93.1%
EBITDA
10.0% | 37.9%
EBIT
-7.6%
Net
-40.4% | 62.8%
Free Cash Flow
27.1%
More
EPS
$-3.8
FCF per Share
$2.6
Short interest
7.4%
Employees
68
Rev per Employee
$2.5m
Show more

Is Ligand Pharmaceuticals Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Ligand Pharmaceuticals Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

Buy
92%
Hold
8%

Financial data from Ligand Pharmaceuticals Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
188 188
41% 41%
100%
- Direct Costs 13 13
19% 19%
7%
175 175
42% 42%
93%
- Selling and Administrative Expenses 89 89
49% 49%
47%
- Research and Development Expense 67 67
199% 199%
36%
19 19
54% 54%
10%
- Depreciation and Amortization 33 33
0% 0%
18%
EBIT (Operating Income) EBIT -14 -14
288% 288%
-8%
Net Profit -76 -76
281% 281%
-40%

In millions USD.

Don't miss a Thing! We will send you all news about Ligand Pharmaceuticals Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ligand Pharmaceuticals Incorporated Stock News

Neutral
GlobeNewsWire
14 days ago
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m.
Neutral
GlobeNewsWire
19 days ago
JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible senior notes due 2030 (the “notes”).
Neutral
GlobeNewsWire
22 days ago
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act o...
More Ligand Pharmaceuticals Incorporated News

Company Profile

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Head office United States
CEO Todd Davis
Employees 68
Founded 1987
Website www.ligand.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today